Publication
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerMalignant Ovarian Neoplasmcivic_curation1.00
- drugOlaparibcivic_curation1.00
- geneBRCA1civic_curation1.00
- geneBRCA2civic_curation1.00
- variantBRCA1 Mutationcivic_curation1.00
- variantBRCA2 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 30345884
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRCA1 Mutation3 | ||||||||
| Olaparib | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID7274In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were rando… (full text at CIViC) PMID 30345884 · Moore et al., 2018 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 1 | accepted | EID7275In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were rando… (full text at CIViC) PMID 30345884 · Moore et al., 2018 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | rejected | EID7277In phase 3 trial for patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had coplete or partial response after platinum-based chemotherapy were treated with ola… (full text at CIViC) PMID 30345884 · Moore et al., 2018 · Open in CIViC | civic |
| BRCA2 Mutation1 | ||||||||
| Olaparib | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID7276In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were rando… (full text at CIViC) PMID 30345884 · Moore et al., 2018 · Open in CIViC | civic |